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Abstract
Background: To evaluate the inhibitory effects of aflibercept on the growth and subretinal invasion of
retinoblastoma.
Methods: Xenotransplantation and orthotopic mouse models were created by injecting Y-79 cells subcutaneously
and intravitreally, respectively. After induction of retinoblastoma, animals were intraperitoneally injected with
aflibercept (25 mg/kg body weight) or saline twice a week for 3 weeks. Tumor size was measured weekly and
compared between the two groups. At 4 weeks, animals were sacrificed and an immunohistochemical examination
was conducted to compare the microvascular density and degree of apoptosis between groups. In addition, the
degree of choroidal invasion was also analyzed in the orthotopic xenotransplantation model. A co-culture system of
Y-79 or WERI-Rb-1 cells and human umbilical vein endothelial cells (HUVECs) was used for in vitro experiments, and
the anti-angiogenic effect of aflibercept was evaluated by analyzing cell numbers.
Results: In the Y-79 xenotransplantation model, aflibercept treatment significantly inhibited tumor growth at
4 weeks versus baseline compared with saline-injected mice (188.53 ± 118.53 mm3 vs. 747.87 ± 118.83 mm3,
respectively, P < 0.001). Tumors isolated from aflibercept-treated mice contained fewer blood vessels (8.59 % ± 7.60 %
vs. 14.91 % ± 4.53 %, respectively, P < 0.05) and an increased number of apoptotic cells (15.10 ± 9.13 vs. 4.44 ± 2.24,
respectively, P < 0.05). In the orthotopic model, the degree of subretinal invasion of tumor cells was significantly
reduced after aflibercept treatment (0.07 ± 0.06 vs. 0.15 ± 0.10, P < 0.05). And addition of aflibercept to co-cultures of
HUVECs and Y-79, WERI-Rb-1 cells significantly reduced HUVEC proliferation.
Conclusions: Aflibercept reduced retinoblastoma angiogenesis in association with a significant reduction in tumor
growth and invasion. These findings suggest that aflibercept could be used in an adjuvant role together with systemic
chemotherapy to reduce tumor size and angiogenesis in retinoblastoma.
Keywords: Aflibercept, Retinoblastoma, Choroidal invasion, Treatment
Background
Retinoblastoma is the most common primary intraocular
tumor in children [1], affecting 11.8 children aged 0–4
years per million in the United States (1975–2004) [2].
External beam radiation therapy has historically been
the main therapeutic option for retinoblastoma [3–6],
but it can be associated with secondary complications,
including radiation-induced cataracts and retinopathy,
and malignant neoplasms such as osteosarcomas [7–9].
Therefore, with advances in chemotherapy has come a
shift in the therapeutic strategy for retinoblastoma from
external beam radiation to systemic chemotherapy.
Currently, chemotherapy (carboplatin, etoposide, and
vincristine) with local consolidation treatment (laser
photocoagulation, cryotherapy and thermotherapy) is
the main therapeutic option for retinoblastoma and
has contributed to an improvement in patient survival
of up to 95 % or more [10, 11].
As the retinoblastoma survival rate has improved, con-
servation of the eyeball and restoration of visual func-
tion have increasingly become important issues,
especially in bilateral retinoblastoma. Based on the Inter-
national Retinoblastoma Classification system, which
classifies tumors from A (least severe) to E (most
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severe), globe salvage rates were found to be 100, 93 and
90 % for eyes classified as A, B and C, respectively [12].
However, in cases of advanced retinoblastoma (groups D
and E), the eyeball salvage rate was still low, despite ad-
vancements in chemotherapy [12–14]. Various new
therapeutic modalities, such as intravitreal chemother-
apy and intraarterial chemotherapy via the ophthalmic
artery, have been tried to improve eyeball salvage rates
[15, 16]. However, these approaches have not proved
sufficient to preserve the eyeball in advanced
retinoblastoma.
Angiogenesis is essential for the survival, rapid growth,
and local invasion of solid tumors [17, 18]. Members of
the vascular endothelial growth factor (VEGF) family are
known to play critical roles in tumor angiogenesis
[19, 20]. A number of studies have reported that
blocking VEGF reduces angiogenesis and tumor mass
in various cancers [21–23]. Notably, anti-VEGF agents,
such as bevacizumab, have been used to treat metastatic
cancer by reducing tumor angiogenesis [24–27].
Angiogenesis in retinoblastoma also plays an import-
ant role in tumor growth and invasion, and the extent of
retinoblastoma angiogenesis could be a prognostic indi-
cator. Specifically, Marback et al. reported that tumor
angiogenesis in retinoblastoma is a prognostic factor for
disease dissemination, and Arean et al. reported a posi-
tive correlation between the intensity of VEGF staining
and mitotic and apoptotic indexes [28, 29]. We previ-
ously demonstrated that retinoblastoma cells express
VEGF mRNA and secrete VEGF protein, which promotes
subsequent proliferation of nearby vascular endothelial
cells. Additionally, we showed that this enhanced tumor
retinoblastoma angiogenesis was significantly reduced and
tumor growth was ultimately decreased following bev-
acizumab treatment [30], Nevertheless, the potential
of anti-VEGF treatment in retinoblastoma remains to
be demonstrated.
Recently, new reagents targeting VEGF have been
developed and approved for the treatment of various
tumors and other ocular diseases [31]. Aflibercept
(Regeneron, NY, USA), a fusion protein combining the
Fc portion of human IgG1 with the principal extracellu-
lar ligand-binding domains of human VEGF receptor 1
(VEGFR1) and VEGFR2, acts as a high-affinity, soluble
decoy VEGF receptor and potent angiogenesis inhibitor.
Preclinical studies have demonstrated potent antitumor
and anti-angiogenic activity of aflibercept against a var-
iety of tumors [32, 33].
We hypothesized that aflibercept treatment of retino-
blastoma would exert anti-angiogenic and antitumor
activities as well as decrease invasive growth to the
choroid. Therefore, we sought to evaluate the effects of
aflibercept on tumor growth, invasion, and angiogenesis
in retinoblastoma using in vivo and in vitro models.
Methods
Chemical and reagents
Aflibercept (Regeneron, NY, USA) was provided by Bayer
(Leverkusen, Germany). Matrigel Matrix Basement
Membrane HC was purchased from BD Biosciences
(San Jose, CA, USA).
Animals
The animal experimental protocol was approved by the
Internal Review Board for Animal Experiments of Asan
Life Science Institute, University of Ulsan College of
Medicine (Seoul, Korea). Female, 4-week-old (14–15 g)
athymic nude mice were purchased from Orient Bio Inc.
(Seoul, Korea) and maintained at 24 °C ± 0.5 °C under a
12-h light/dark cycle with free access to food and water
before and after experiments.
Y-79 and WERI-Rb-1 human retinoblastoma cell culture
The Y-79 and WERI-Rb-1 human retinoblastoma cell
lines were purchased from American Type Culture Col-
lection (ATCC, Manassas, VA, USA). The Y-79 cell line
was cultured in Roswell Park Memorial Institute
medium (RPMI; Invitrogen, Carlsbad, CA, USA) con-
taining 20 % fetal bovine serum (Invitrogen) and 1 %
penicillin-streptomycin (Lonza, Allendale, NJ, USA). The
WERI-Rb-1 cell line was cultured in RPMI containing
10 % fetal bovine serum and 1 % penicillin-streptomycin
at 37 °C in a humidified 5 % CO2 incubator.
Xenotransplantation model
Four-week-old female athymic nude mice were used for
the xenotransplantation model. The animals were
injected subcutaneously in the right subaxillary region
with 1.5 × 107 Y-79 cells in 0.3 ml of a 1:1 mixture of
Matrigel Matrix HC and RPMI with 20 % bovine serum
(Invitrogen). Matrigel Matrix HC was used to enhance
the success rate of xenografts [34, 35]. One week after
subcutaneous Y-79 cell injection, animals were evaluated
for successfully transplantation of tumors. Mice in which
injected Y-79 cells were successfully transplanted (tumor
volume > 200 mm3) were divided into two groups and
injected intraperitoneally with aflibercept (25 mg/kg) or
an equal volume of saline twice weekly for 3 weeks
[33, 36–41]. The operator who injected aflibercept or
saline was blinded to group assignments. Tumor sizes
and body weights of mice were measured once
weekly. The longest and shortest dimensions of the
tumor were measured, and the volume of each tumor
was calculated using the modified ellipsoidal formula
[42, 43], where tumor volume = (the longest diameter ×
the shortest diameter2)/2. Four weeks after xenotrans-
plantation, tumors were harvested for tumor weight mea-
surements and immunohistochemical assessments.
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Orthotopic xenotransplantation model
Four-week-old female athymic nude mice were also used
for the orthotopic xenotransplantation model. After
obtaining a fundus image of each mouse with MICRON
III (Phoenix, CA, USA), 1 × 105 (1 μl) Y-79 or WERI-Rb-
1 cells were injected into the vitreous using a 30-gauge
Hamilton syringe [44–46]. A fundus image of each
mouse was also obtained 2 weeks after intravitreal Y-79
or WERI-Rb-1 cells injection to confirm that injected Y-
79 or WERI-Rb-1 cells were successfully transplanted.
Mice in which injected Y-79 or WERI-Rb-1 cells were
successfully transplanted were randomly assigned to two
groups: an aflibercept treatment group and a saline
treatment group. For the orthotopic transplantation
model, intraperitoneal injections of aflibercept or saline
were repeated twice weekly for 3 weeks. Five weeks after
orthotopic transplantation, a fundus image of each
mouse was obtained with MICRON III and the eyeball
was enucleated to evaluate choroidal invasion and apop-
tosis of the retinoblastoma.
Immunohistochemistry for microvessels
After harvesting, tumor tissue was frozen rapidly and
stored at −80 °C. For immunohistochemical examin-
ation, tissues were sectioned at 10 μm intervals using a
cryostat. After fixation with 4 % paraformaldehyde
(PFA), the sections were incubated in permeabilizing
and blocking solution composed of phosphate-buffered
saline (PBS) containing 1 % bovine serum albumin
(BSA) and 0.2 % Triton X-100. Each section was immu-
nostained with isolectin (B4-594; Molecular Probes,
Carlsbad, CA, USA), which binds to perivascular cells
and endothelial cells.
Microvascular density analysis in xenotransplantation
model
Microvascular density was quantified by analyzing the
fraction of lectin-positive pixels per total field using a
computer-assisted method [47]. Briefly, the images were
binarized to black and white with a common threshold
level, such that white pixels represent lectin-positive
cells. The fraction of white pixels, representing lectin-
stained blood vessels, was automatically quantified by
histogram analysis using Adobe Photoshop CS4 (Adobe
Inc., Mountain View, CA, USA). For Microvascular
density quantification, three fields of each section were
used (Additional file 1: Figure S1).
TUNEL staining
The degree of apoptosis was determined using a ter-
minal dUTP nick-end labeling (TUNEL) kit, as described
by the manufacturer (Roche, Basel, Switzerland). Briefly,
frozen sections were fixed with 4 % PFA for 20 min at
room temperature. After incubated in 0.2 % Triton X-
100 in 0.1 % sodium citrate (SSC) buffer, the sections
were stained with TUNEL reagent. Fixed cells were
then incubated in a nucleotide mixture containing
fluorescein-12-dUTP and TdT (terminal transferase)
at 37 °C humid chamber for 60 min. Apoptosis of
xenotransplantation model was quantified by counting
the number of TUNEL-positive cells in four fields of
each section (area, 439.377 × 330.769 μm2/image) [48, 49].
For quantification of apoptosis in orthotopic xenotrans-
plantation model, three images (two center and one per-
ipheral retina; area, 877.148 × 660.329 μm2/image) from
largest eyeball section were captured. Number of TUNEL-
positive cells were counted and the operator who counted
TUNEL-positive cells was blinded to group assignments.
Quantification of subretinal invasion in the orthotopic
xenotransplantation model
The largest eyeball section was used for image analysis
in the orthotopic xenotransplantation model. Sections
were stained using a standard hematoxylin and eosin
(H&E) staining protocol, and the whole eyeball area and
the subretinal invasion area were manually traced using
ImageJ software. Areas were quantified using the program’s
“measure” function, yielding a numerical result in pixels.
The amount of subretinal invasion was quantified by calcu-
lating the ratio of the subretinal invasion area to the entire
eyeball area. The percentage of retinal layer integrity pre-
served was also analyzed (Additional file 2: Figure S2).
Retinoblastoma cell and HUVEC co-culture model
To analyze the effect of aflibercept on endothelial cell
proliferation in vitro, we conducted studies using human
umbilical vein endothelial cells (HUVECs) co-cultured
with Y-79 cells or WERI-Rb-1 cells. HUVECs and culture
media were purchased from Lonza. The co-culture system
was prepared by first plating HUVECs onto 6-well tissue
culture plates (0.5 × 105 cells/well) and incubating them
for 24 h, at which point HUVECs adhered strongly to the
floors of the wells. HUVECs were cultured in Endothelial
Growth Media (EGM) on fibronectin-coated plates at
37 °C in a humidified 5 % CO2 incubator. After 1 day, the
medium was then replaced with a mixed medium of RPMI
and EGM (1:1), and Y-79 cells (1 × 105 cells/well) or
WERI-Rb-1 cells (1 × 105 cells/well) were added.
Cell proliferation
The co-cultured Y-79 cells, WERI-Rb-1 cells and HUVECs
were treated with 1 mg/ml aflibercept for 3 days. Untreated,
co-cultured cells incubated for 3 days served as controls.
Three days after aflibercept treatment, proliferation of
HUVECs in co-culture with Y-79 or WERI-Rb-1 cells were
assessed. After removing Y-79 or WERI-Rb-1 cells,
HUVECs were fixed with 4 % PFA for 15 min at room
temperature and stained with DAPI (4′,6-diamidino-2-
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phenylindole). HUVEC proliferation was quantified by
counting the number of DAPI-positive cells in four fields of
HUVECs (area, 439.377 × 330.769 μm2/image).
Statistical analysis
All results are presented as means ± SEM (standard
error of the mean). Student’s t-tests were used to
evaluate the significance of differences between two
groups. P-values < 0.05 were considered statistically
significant. SPSS version 21.0 (SPSS, Inc., Chicago, IL,
USA) was used to perform all analyses, and graphical
presentations were created using Sigma Plot version 10.0
software (Systat Software, Inc., San Jose, CA, USA).
Results
Xenotransplantation model
Xenotransplantation model mice, prepared by injecting
Y-79 human retinoblastoma cells as described in Materials
and Methods, were treated with aflibercept or saline and
their tumors were assessed. Macroscopically, retinoblasto-
mas from aflibercept-treated mice appeared smaller than
those from saline-injected mice (Fig. 1a). Quantification of
tumor volumes confirmed this finding, showing that
aflibercept treatment prevented tumor volumes of
retinoblastoma from significantly increasing (Fig. 1c). Spe-
cifically, at the time mice were divided into subgroups
(1 week after Y-79 cell injection), tumor volumes were not
different between aflibercept-treated mice (289 ± 71 mm3)
and saline-injected mice (294 ± 78 mm3; P = 0.842). After
treatment for 3 weeks, tumor volumes in the aflibercept
treatment group (189 ± 119 mm3) remained unchanged
compared with their starting volume (289 ± 71 mm3),
whereas tumor volumes of saline-injected mice were sig-
nificantly increased from 294 ± 78 mm3 to 748 ± 119 mm3.
As shown in Fig. 1d, tumor weights in the aflibercept-
treated group (0.11 ± 0.08 g) were also significantly less
than those in saline-injected mice (0.47 ± 0.51 g; P < 0.05).
The mean weight change of mice in aflibercept-treated
and saline-injected was not different (Fig. 1b).
Reduced angiogenesis in tumor tissue of mice after
aflibercept treatment
H&E staining of tumor tissue obtained 4 weeks after Y-79
cell xenotransplantation (3 weeks after aflibercept or sa-
line treatment) showed that the cell density of xenotrans-
planted retinoblastomas in the aflibercept-treated group
was lower than that in the saline-injected group (Fig. 2a,
Additional file 1: Figure S1). There were also substantially
Fig. 1 Tumor volume and weight changes in the xenotransplantation model. a Representative macroscopic appearance of the xenotransplantation
model 4 weeks after injection of Y-79 cells. Tumors were smaller in aflibercept-treated mice (n = 21) compared with those in saline-injected group
(n = 21). b Body weight changes in the xenotransplantation model. Four weeks after Y-79 cell injection, body weights were not different between the
two groups (c) Tumor volume changes in the xenotransplantation model. Whereas tumor volume significantly increased in the saline-injected group
(#P < 0.005, ##P < 0.001), it remained unchanged in the aflibercept (25 mg/kg) treatment group. d Tumor weight changes in the xenotransplantation
model. Tumor weights in the saline-injected group were also significantly heavier compared to those in the aflibercept treatment group (*P < 0.05)
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fewer vascular endothelial cells within tumor vessels in
the aflibercept-treated group (Fig. 2a). To confirm that
aflibercept treatment reduced tumor-induced angiogenesis,
we stained for blood vessels using lectin. Lectin staining
showed that microvascular density in the aflibercept group
was less than that in the saline-injected group (Fig. 2b).
This was confirmed by a quantitative analysis of lectin-
positive cells (Fig. 2c), which showed that the percentage of
microvascular coverage in the aflibercept-treated group
(8.59 % ± 7.60 %) was significantly less than that (P < 0.05)
in the saline-injected group (14.91 % ± 4.53 %).
Increased apoptosis in aflibercept-treated mice
To determine whether the reduction in angiogenesis in
tumors after aflibercept treatment ultimately led to an
increase in apoptotic cell death of retinoblastoma cells,
we performed TUNEL staining. The number of TUNEL-
positive cells was increased in the aflibercept treatment
group compared with the saline-injected group (Fig. 3a).
As shown in Fig. 3b, the number of apoptotic (TUNEL-
positive) cells was increased ~2-fold in tumors of
aflibercept-treated mice (15.10 ± 9.13) compared with
that in saline-injected group (4.44 ± 2.24; P < 0.05).
Reduced subretinal invasion and tumor angiogenesis in
the orthotopic xenotransplantation model after
aflibercept treatment
After intravitreal injection, Y-79 tumor cells proliferated
in the vitreous cavity, leading to worsening of vitreous
haziness (Fig. 4). To determine whether aflibercept treat-
ment reduced subretinal invasion of retinoblastoma, we
performed H&E staining and quantification of subretinal
invasion (Fig. 5a, Additional file 2: Figure S2). As shown
in Fig. 5b, mice in the aflibercept treatment group
Fig. 2 Aflibercept treatment suppresses tumor angiogenesis in a xenotransplantation model. a H&E-stained tumor tissue sections. Retinoblastoma
cell density was reduced in the aflibercept treatment group compared with that in the saline-injected group. Substantially fewer vascular endothelial
cells were detected in the aflibercept-treated group. b Representative lectin staining (green) of microvessels in tumor sections. Microvascular density in
the aflibercept group was significantly lower than that in the saline-injected group. c Quantification of microvascular density (*P < 0.05). Original
magnification, ×200; scale bar, 200 μm
Fig. 3 Apoptosis in a xenotransplantation model is increased after aflibercept treatment. a Fluorescence photomicrographs of TUNEL staining
(green) in tumor tissue sections. b Quantification of TUNEL staining. The number of TUNEL-positive cells was significantly increased in the aflibercept
group compared with the saline-injected group (#P < 0.005). Original magnification, ×400; scale bar, 200 μm
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showed a significant reduction in the subretinal invasion
of retinoblastoma (aflibercept-treated, 0.07 ± 0.06; saline-
injected, 0.15 ± 0.10, P < 0.05). In association with this
reduction in subretinal invasion of retinoblastoma, apop-
tosis was significantly increased (Fig. 5c,d) and retinal
layer integrity was preserved in the aflibercept-treated
group (12/14 [85.7 %]) compared with the saline-
injected group (1/8 [12.5 %] P < 0.05). Like Y-79 cells,
WERI-Rb-1 cells were well proliferated after intravitreal
injection (Additional file 3: Figure S3A). However, unlike
orthotopic xenotransplantation model with Y-79 cell,
WERI-Rb-1 cell was not invaded into the subretinal
space (Additional file 3: Figure S3B). Because the lack of
invasiveness of WERI-Rb-1 cells rendered the orthotopic
xenotransplantation model unsuccessful, we were unable
to use it in the present study. And several previous stud-
ies also reported the poor invasiveness of WERI-Rb-1
cells into the subretinal space [50, 51].
Reduced HUVEC proliferation following aflibercept
treatment
To test the effect of aflibercept on retinoblastoma cell-
induced vascular endothelial cell proliferation, we con-
ducted an in vitro study used co-cultured HUVECs and
Y-79 cells. DAPI staining showed that HUVEC prolifera-
tion was increased by co-culture with Y-79 cells, an
Fig. 4 Suppressed Y-79 cell proliferation in the vitreous cavity after aflibercept treatment. As the tumor proliferated in the vitreous cavity, vitreous
haziness became worse. 5 weeks after intravitreal injection of Y-79 cells, vitreous haziness which represented Y-79 cells proliferation was worse in
the saline-injected group (n = 8), compared with that in the aflibercept treatment group (n = 14)
Fig. 5 Aflibercept treatment suppressed retinoblastoma subretinal invasion and increased apoptosis in an orthotopic xenotransplantation model.
a Representative H&E staining of the orthotopic xenotransplantation model. Subretinal invasion sizes were smaller in aflibercept-treated mice
(n = 14) than in saline-injected group (n = 8). Original magnification, ×40; scale bar, 500 μm. b Quantification of subretinal invasion. Retinoblastoma
subretinal invasion was significantly reduced after aflibercept treatment compared with the saline-injected group (*P < 0.05, **P < 0.01). c Representative
TUNEL staining (green) of the orthotopic xenotransplantation model. TUNEL positive cells were significantly increased in aflibercept treatment group.
Original magnification, ×200; scale bar, 200 μm. d Quantification of TUNEL positive apoptosis cell number (*P < 0.05)
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effect that was attenuated by treatment with aflibercept
(Fig. 6a). Quantification of DAPI-stained HUVECs by
cell counting confirmed this effect, showing a significant
reduction in the proliferation of HUVECs after afliber-
cept treatment of HUVEC and Y-79 cell co-cultures
(Fig. 6b). We also found that WERI-Rb-1 cells increased
HUVEC proliferation and WERI-Rb-1 cell induced
angiogenesis was also significantly inhibited by afliber-
cept treatment (Fig. 6c,d).
Discussion
The primary finding of this study is that aflibercept
treatment is capable of inhibiting retinoblastoma tumor
growth and invasion. Moreover, aflibercept treatment
significantly reduced tumor vessel density and induced
apoptosis in the tumor mass. In vitro results further
showed that HUVEC proliferation increased when co-
cultured with Y-79 cells, an effect that was attenuated by
aflibercept treatment. Angiogenesis in retinoblastoma
plays an important role in tumor growth and local inva-
sion, and the amount of angiogenesis in the retinoblast-
oma tumor has been suggested to be a prognostic factor
[28, 29]. Therefore, aflibercept treatment could have
therapeutic efficacy against retinoblastoma by reducing
tumor angiogenesis.
Retinoblastoma is the most common primary intraoc-
ular tumor in children [1]. The overall incidence of ret-
inoblastoma in Korea, determined between 1993 and
2010, was 11.2 per 1,000,000 children aged 0 to 4 [52]. If
untreated, retinoblastoma can lead to death because of
distant metastasis [53, 54]. With advances in systemic
chemotherapy, the main therapeutic option for retinoblast-
oma treatment has become chemotherapy (carboplatin,
etoposide, and vincristine) with local consolidation treat-
ment (laser photocoagulation, cryotherapy and thermother-
apy), which have contributed to an improvement in patient
survival up to 95 % or more [10, 11]. Park et al. reported
that the all-cause mortality rate of retinoblastoma in Korea
was 7.9 % at 5 years and 8.4 % at 10 years [52].
With this improvement in the survival rate of retino-
blastoma patients, globe salvage has become an import-
ant issue in retinoblastoma treatment. In advanced-stage
retinoblastoma (Group D and E), globe salvage rate has
remained low. Okimoto et al. reported that, despite sys-
temic chemotherapy, the globe salvage rate of group D
was 33.0 %, and both Okimoto et al. and Naseripour
et al. [13, 14] reported a globe salvage rate of 0 % for
group E retinoblastoma. To improve the rate of globe
salvage, researchers have tested new therapeutic modal-
ities, such as intravitreal chemotherapy and intraarterial
chemotherapy via ophthalmic artery [15, 16]. However,
those methods were not enough to save the eyeball in
advanced retinoblastoma.
Subretinal and optic nerve infiltration of retinoblast-
oma are cited as the most common causes of failure to
save the eyeball after systemic chemotherapy [15, 16].
And angiogenesis might be essential for invasion of ret-
inoblastoma into the subretinal space or optic nerve
[28], and several studies have reported a relationship be-
tween angiogenesis and tumor invasion or disease
Fig. 6 Effect of aflibercept on proliferation of HUVECs co-cultured with Y-79 or WERI-Rb-1 cells. a Fluorescence photomicrographs of DAPI staining
(blue) in HUVEC co-cultures. Image showing HUVECs alone or HUVECs co-cultured with Y-79, with or without treatment with 1 mg/ml aflibercept.
b Quantification of cell number. The number of HUVECs was increased by co-culture with Y-79 cells and attenuated by treatment with aflibercept
(n = 4, *P < 0.05). c Fluorescence photomicrographs of DAPI staining (blue) in HUVEC co-cultures. Image showing HUVECs alone or HUVECs co-cultured
with WERI-Rb-1, with or without treatment with 1 mg/ml aflibercept. d Quantification of cell number. The number of HUVECs was increased by
co-culture with WERI-Rb-1 cells and attenuated by treatment with aflibercept (n = 4, ##P < 0.001, *P < 0.05). Original magnification, ×400;
scale bar, 100 μm
Kim et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:171 Page 7 of 10
dissemination [28, 55–57]. Therefore, if retinoblastoma
angiogenesis could be blocked, it should be possible
to reduce subretinal or optic nerve infiltration of
retinoblastoma, which eventually might improve the
globe salvage rate.
Previous studies have demonstrated that retinoblast-
oma cells express VEGF in hypoxic and normoxic condi-
tions [29, 30, 58]. Moreover, HUVEC proliferation is
increased by co-culture with Y-79 cells and reduced by
bevacizumab treatment [30]. In vitro experiments per-
formed in the current study also evaluated the anti-
angiogenic effects of aflibercept on co-cultured HUVECs
and Y-79 retinoblastoma cells, demonstrating that afli-
bercept also reduced HUVEC proliferation in HUVEC
and Y-79 retinoblastoma cell co-cultures. Thus, afliber-
cept treatment is capable of reducing retinoblastoma-
induced angiogenesis in vitro.
In the current study, we found that aflibercept treat-
ment reduced tumor growth and invasion to the chor-
oid. To determine whether the suppressed tumor growth
and invasion after aflibercept treatment resulted from
decreased tumor angiogenesis, we assessed the extent of
angiogenesis in the xenotransplanted retinoblastoma
after aflibercept treatment by performing immunohisto-
chemical staining with the vascular endothelial cell
marker, lectin. These experiments showed a substantial
decrease in lectin-positive cells within tumors after afli-
bercept treatment compared with the saline-injected
group. These findings indicate that injected aflibercept
reduced angiogenesis within the retinoblastoma, ultim-
ately decreasing tumor volume. We also found that sub-
retinal invasion of the orthotopic xenotransplantation
model was significantly reduced after aflibercept treat-
ment. Decreased subretinal invasion after aflibercept
treatment reflected that aflibercept treatment could ac-
tually decrease subretinal invasion in the eyeball, which
leaded to improve glove salvage rate.
TUNEL staining, performed to evaluate the effect of
the aflibercept-induced decrease in angiogenesis on the
extent of apoptosis in the tumor mass, showed that this
decrease in angiogenesis was associated with an increase
in apoptosis. Similar results were obtained by Theodoro-
poulou et al., who reported that aminoimidazole carbox-
amide ribonucleotide (AICAR) treatment decreased
tumor angiogenesis in association with an increase in
tumor cell apoptosis [59]. Although it is reasonable to
suppose that reduced angiogenesis in the xenotrans-
planted tumor would increase apoptosis and eventually
prevent tumor enlargement, how aflibercept treatment
of retinoblastoma increases apoptosis is currently un-
known. Notable in this context, aflibercept was not cyto-
toxic toward retinoblastoma cells. Instead, aflibercept
reduced the growth and invasion of retinoblastoma by
reducing angiogenesis. Therefore, we assume that, by
reducing tumor angiogenesis in the retinoblastoma, afli-
bercept treatment could have an adjuvant role together
with systemic chemotherapy. Accordingly, we would ex-
pect combined treatment with systemic chemotherapy
and aflibercept to decrease optic nerve and choroidal in-
vasion by reducing angiogenesis, ultimately improving
the rate of eyeball salvage. However, considering the fact
that such malignancies as colon, or breast cancer, that
responded well to initial anti-VEGF treatment, eventu-
ally developed anti-VEFG resistance, a long-term anti-
VEGF treatment to retinoblastoma could potentially
show anti-VEGF resistance. Therefore, long-term anti-
angiogenic effect of aflibercept to retinoblastoma should
be further evaluated [60].
Conclusion
We found that aflibercept reduced retinoblastoma angio-
genesis in vitro as well as in in vivo xenotransplantation
models. As a result of the reduction in retinoblastoma
angiogenesis after aflibercept injection, tumor volume
did not significantly increase in the xenotransplantation
model and tumor invasion decreased in the orthotopic
xenotransplantation model. Therefore, aflibercept treat-
ment in retinoblastoma could play an adjuvant role in
reducing tumor size and invasion when combined with
systemic chemotherapy.
Additional files
Additional file 1: Figure S1. Automated quantification of angiogenesis
in the xenotransplantation model. Upper row showed Lectin staining
(green) of microvessels in tumor sections. Lower row represented
binarized image (black and white) of Lectin staining. Images were
binarized to black and white with a common threshold level, such that
white pixels represent lectin-positive cells. The fraction of white pixels,
representing lectin-stained blood vessels, was automatically quantified by
histogram analysis using Adobe Photoshop CS4. (TIF 706 kb)
Additional file 2: Figure S2. Quantification of subretinal invasion in the
orthotopic xenotransplantation model. Eyeball sections were stained
using a standard hematoxylin and eosin (H&E) staining protocol, and the
whole eyeball area and the subretinal invasion area were manually traced
using ImageJ software. Areas were quantified using the program’s
“measure” function, yielding a numerical result in pixels. The amount of
subretinal invasion was quantified by calculating the ratio of the
subretinal invasion area to the entire eyeball area. (TIF 1041 kb)
Additional file 3: Figure S3. In Vivo and In vitro experiment with WERI-
Rb-1 cell. (A) MICRON image of orthotopic xenotransplantation model
with WERI-Rb-1 cells. Five weeks after WERI-Rb-1 cell intravitreal injection,
vitreous haziness became worse. (B) Representative H&E staining of the
orthotopic xenotransplantation model with WERI-Rb-1 cell. Though WERI-
Rb-1 cell was proliferated in the vitreous cavity, there was no subretinal
invasion in the orthotopic xenotransplantation model with WERI-Rb-1 cell
(saline = 9, aflibercept = 13). (TIF 2898 kb)
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